Claims for Patent: 7,507,873

Summary for Patent: 7,507,873

Title:	Transgenic avians containing recombinant ovomucoid promoters
Abstract:	Transgenic avians having a recombinant ovomucoid gene expression controlling region operably linked to one or more useful amino acid coding sequences.
Inventor(s):	Harvey; Alex J. (Athens, GA), Leavitt; Markley C. (Watkinsville, GA), Wang; Youliang (Monroe, GA)
Assignee:	AviGenics, Inc. (Athens, GA)
Application Number:	11/649,543
Patent Claims:	1. A transgenic avian comprising a nucleic acid sequence encoding a heterologous protein operably linked to an ovomucoid promoter that is at least 95% identical to the nucleotide sequence of about 34,473 to about 36,248 of SEQ ID NO: 36, wherein the heterologous protein is produced in an oviduct cell of the avian. 2. The transgenic avian of claim 1, wherein the nucleic acid sequence comprises a signal sequence coding region. 3. The transgenic avian of claim 1, wherein the nucleic acid sequence comprises an IRES. 4. The transgenic avian of claim 1, wherein the nucleic acid sequence further comprises a vector. 5. The transgenic avian of claim 4, wherein the vector is selected from the group consisting of a plasmid, a viral vector, and an artificial chromosome. 6. The transgenic avian of claim 1, wherein the nucleic acid sequence further comprises a retrovirus vector. 7. The transgenic avian of claim 1, wherein the ovomucoid promoter comprises a nucleotide sequence that is at least 99% identical to the nucleotide sequence of about 34,473 to about 36,248 of SEQ ID NO: 36. 8. The transgenic avian of claim 1, wherein the ovomucoid promoter comprises the nucleotide sequence of about 34,473 to about 36,248 of SEQ ID NO: 36. 9. The transgenic avian of claim 1, wherein the transgenic avian is a chicken or a quail. 10. The transgenic avian of claim 1, wherein the transgenic avian is a chicken. 11. The transgenic avian of claim 1 wherein the oviduct cell is tubular gland cell. 12. The transgenic avian of claim 1 wherein a the nucleic acid sequence encodes at least one heterologous amino acid sequence selected from the group consisting of an immunoglobulin heavy chain variable region, an immunoglobulin heavy chain comprising a variable region and a constant region, an immunoglobulin light chain variable region, an immunoglobulin light chain comprising a variable region and a constant region, and a single-chain antibody comprising two peptide-linked immunoglobulin variable regions. 13. The transgenic avian of claim 1 wherein the heterologous protein is an antibody is selected from the group consisting of IgG, IgA, IgD, IgM and IgE. 14. The transgenic avian of claim 1 wherein the therapeutic protein is selected from the group consisting of erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), CTLA4-Fc, interferon, interferon alpha, interferon beta1a, interferon beta1b, FSH and beta glucocerebrosidase. 15. The transgenic avian of claim 1 wherein the therapeutic protein is selected from the group consisting of marine MAb directed against t-lymphocyte antigen CD3, marine MAb directed against TAG-72, tumor-associated glycoprotein, FAb fragments derived from chimeric MAb directed against platelet surface receptor GPII(b)/III(a), murine MAb fragment directed against tumor-associated antigen CA 125, murine MAb fragment directed against human carcinoembryonic antigen, CEA, murine MAb fragment directed against human cardiac myosin, murine MAb fragment directed against tumor surface antigen PSMA, murine MAb fragments (EAb/FAb2 mix) directed against HMW-MAA, murine MAb fragment (FAb) directed against carcinoma-associated antigen, MAb fragments (FAb) directed against NCA 90, a surface granulocyte nonspecific cross reacting antigen, chimeric MAb directed against CD20 antigen found on surface of B lymphocytes, humanized MAb directed against the alpha chain of the IL2 receptor, chimeric MAb directed against the alpha chain of the IL2 receptor, chimeric MAb directed against TNF-alpha, humanized MAb directed against an epitope on the surface of respiratory synctial virus, humanized MAb directed against HER 2, i.e., human epidermal growth factor receptor 2, human MAb directed against cytokeratin tumor-associated antigen, anti-CTLA4, donase-alpha DNAse, TNF-alpha, IL-2-diptheria toxin fusion protein that targets cells displaying a surface IL-2 receptor, TNFR-1gG fragment fusion protein, enbrel, laronidase, teriparatide and parathyroid hormone derivatives. 16. The transgenic avian of claim 1, wherein the heterologous protein is a therapeutic protein. 17. The transgenic avian of claim 1, wherein the heterologous protein is a fusion protein. 18. The transgenic avian of claim 16, wherein the therapeutic protein is selected from the group consisting of immunoglobulins, antibodies, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), CTLA4-Fc, interferon, interferon alpha, interferon beta1a, interferon beta1b, follicle stimulating hormone (FSH) and beta glucocerebrosidase. human epidermal growth factor receptor 2 (HER 2) follicle stimulating hormone (FSH). 19. The transgenic chicken of claim 16 wherein the therapeutic protein is selected from the group consisting of murine MAb, directed against t-lymphocyte antigen CD3, murine MAb directed against TAG-72, tumor-associated glycoprotein, FAb fragments derived from chimeric MAb directed against platelet surface receptor GPII(b)/III(a), murine MAb fragment directed against tumor-associated antigen CA 125, murine MAb fragment directed against human carcinoembryonic antigen, CEA, murine MAb fragment directed against human cardiac myosin, murine MAb fragment directed against tumor surface antigen PSMA, murine MAb fragments (FAb/FAb2 mix) directed against HMW-MAA, murine MAb fragment (FAb) directed against carcinoma-associated antigen, MAb fragments (FAb) directed against NCA 90, a surface granulocyte nonspecific cross reacting antigen, humanized MAb directed against the alpha chain of the IL2 receptor, chimeric MAb directed against the alpha chain of the IL2 receptor, chimeric MAb directed against TNF-alpha, humanized MAb directed against an epitope on the surface of respiratory synctial virus, humanized MAb directed against human epidermal growth factor receptor 2 (HER 2) human MAb, directed against cytokeratin tumor-associated antigen, anti-CTLA4, chimeric MAb directed. against CD 20 surface antigen of B lymphocytes, dornase-alpha DNAse, TNF-alpha, IL-2-diptheria toxin fusion protein that targets cells displaying a surface IL-2 receptor, TNFR-1gG fragment fusion protein, enbrel, laronidase, teriparatide and parathyroid hormone derivatives. 20. The transgenic avian of claim 1 wherein the heterologous protein is selected from the group consisting of erythropoietiu (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), CTLA4-Fc, interferon, interferon alpha, interferon beta1a, interferon beta1b, follicle stimulating hormone (FSH) and beta glucocerebrosidase.

Details for Patent 7,507,873

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2021-11-30
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2021-11-30
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2021-11-30
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2021-11-30
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2021-11-30
Immunex Corporation	ENBREL	etanercept	Injection	103795			2021-11-30